HER2-POSITIVE METASTATIC BREAST CANCER
Clinical trials for HER2-POSITIVE METASTATIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE METASTATIC BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
First human trial launches for experimental cancer 'Breaker' drug
Disease control Recruiting nowThis is the first human study testing a new experimental drug called BBO-10203 in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to find safe doses and see how the body processes the drug, both alone and when combined with oth…
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New scan could match patients to best drug after treatment fails
Disease control Recruiting nowThis study is for people with advanced HER2-positive breast cancer whose disease has worsened on a specific drug (T-DXd). It tests if a special imaging scan (HER2-PET/CT) can predict who might benefit from switching to another targeted drug (T-DM1). Patients get the scan and a bi…
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: Jules Bordet Institute • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New Triple-Threat attack on breast Cancer's most devastating spread
Disease control Recruiting nowThis study is testing a combination of three drugs to treat a serious complication where HER2-positive breast cancer spreads to the fluid-filled lining around the brain and spinal cord. It aims to see if this approach can help patients live longer and improve their neurological s…
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC
-
New test aims to predict who will benefit from advanced breast cancer drug
Diagnosis Recruiting nowThis study is testing whether a new, more precise way to measure the HER2 protein in breast cancer tumors can better predict which patients will respond to the targeted drug Enhertu (T-DXd). Researchers will enroll 200 adults with a specific type of metastatic breast cancer (HER2…
Matched conditions: HER2-POSITIVE METASTATIC BREAST CANCER
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Diagnosis
Last updated Feb 23, 2026 14:52 UTC